Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.309,43-0,03 %

Gold3.368,67-0,59 %

Öl (Brent)76,30-0,15 %

Dow Jones42.157,60-0,09 %

US Tech 10021.711,42-0,03 %

EUR/USD1,14795-0,04 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

UroGen Pharma Aktie

Aktie

ISIN: IL0011407140 WKN: A2DTCV Land Flagge IL

Israel

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

12,950

EUR

+12,12 %

+1,400 EUR

Letzter Kurs 23:00:21 Lang & Schwarz

UroGen Pharma Aktie kaufen

Geldkurs

23:00:21

12,700

EUR

883 STK

Briefkurs

23:00:21

13,200

EUR

883 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN 16.06.25 · newsfile · UroGen Pharma
URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before Expiration of July 28 Class Action Deadline 15.06.25 · newsfile · UroGen Pharma
ROSEN, SKILLED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN 13.06.25 · newsfile · UroGen Pharma
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP 13.06.25 · newsfile · UroGen Pharma
URGN CLASS ACTION NEWS: UroGen Pharma Ltd. Shareholders that Suffered Losses are Alerted of the Upcoming July 28 Securities Fraud Class Action Deadline 13.06.25 · newsfile · UroGen Pharma
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit 12.06.25 · newsfile · UroGen Pharma
U.S. FDA Approves UroGen’s ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) 12.06.25 · Business Wire (engl.) · UroGen Pharma
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN 11.06.25 · newsfile · UroGen Pharma
URGN LEGAL ALERT: BFA Law Notifies UroGen Pharma Ltd. Investors of the Imminent July 28 Securities Fraud Class Action Deadline 11.06.25 · newsfile · UroGen Pharma
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN 11.06.25 · newsfile · UroGen Pharma
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman 11.06.25 · newsfile · UroGen Pharma
URGN LEGAL NEWS: UroGen Pharma Ltd. Investors with Losses are Notified to Contact BFA Law about the Pending Class Action Lawsuit 10.06.25 · newsfile · UroGen Pharma

1
2
3
4
5
…
8

Meistgelesen

7 Tage
30 Tage
12 Monate

U.S. FDA Approves UroGen’s ZUSDURI (mitomycin) for Intravesical Solution as the First and Only ... 180 Leser
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... 176 Leser
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & ... 152 Leser
URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before ... 152 Leser
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors ... 120 Leser
ROSEN, SKILLED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before ... 120 Leser
URGN CLASS ACTION NEWS: UroGen Pharma Ltd. Shareholders that Suffered Losses are Alerted of the ... 108 Leser

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... 184 Leser
U.S. FDA Approves UroGen’s ZUSDURI (mitomycin) for Intravesical Solution as the First and Only ... 180 Leser
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... 176 Leser
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff ... 164 Leser
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & ... 152 Leser
URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before ... 152 Leser
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of ... 152 Leser
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors ... 140 Leser
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 136 Leser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ... 132 Leser

Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost ... 256 Leser
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... 184 Leser
U.S. FDA Approves UroGen’s ZUSDURI (mitomycin) for Intravesical Solution as the First and Only ... 180 Leser
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... 176 Leser
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost ... 176 Leser
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff ... 164 Leser
URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before ... 152 Leser
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & ... 152 Leser
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of ... 152 Leser
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update 148 Leser